SAN DIEGO, July 17, 2020 /PRNewswire/ -- DelMar
Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the
"Company"), a biopharmaceutical company focused on the development
of new solid tumor cancer therapies announced today that it will be
conducting a conference call to discuss the Company's previously
announced proposed acquisition of Adgero BioPharmaceuticals
Holdings, Inc.. The call will be held Thursday, July 23, 2020 at 4:30PM ET.
Conference Call Dial-In and Webcast Details
The call
will include remarks by Saiid
Zarrabian, president and CEO, Scott
Praill, chief financial officer and Greg Johnson, senior VP of Operations. A slide
presentation will accompany the call and can be accessed via the
webcast link below. Please refer to the information below for
conference call dial-in information and webcast registration.
Participants may dial in by calling: 1-877-270-2148 (domestic)
or 1-412-902-6510 (international). All callers should dial in
approximately 10 minutes prior to the scheduled start time and ask
to be joined into the DelMar Pharmaceuticals Conference Call.
The conference call will also be available through a live
webcast with an accompanying presentation which can be accessed
through the following link:
https://services.choruscall.com/links/dmpi200723.html
About DelMar Pharmaceuticals, Inc.
Located in San Diego,
California, DelMar is focused on the development and
commercialization of new therapies for cancer patients who have
limited or no treatment options. By focusing on understanding tumor
biology and mechanisms of treatment resistance, the Company
identifies biomarkers to personalize new therapies in indications
where patients are failing, or are unable to tolerate,
standard-of-care treatments.
The Company's current pipeline is based around VAL-083, a
"first-in-class", small-molecule chemotherapeutic with a novel
mechanism of action that has demonstrated clinical activity against
a range of cancers, including central nervous system, ovarian and
other solid tumors (e.g. NSCLC, bladder cancer, head and neck) in
U.S. clinical trials sponsored by the National Cancer Institute
(NCI). Based on DelMar's internal research programs and these prior
NCI-sponsored clinical studies, the Company is conducting clinical
trials to support the development and commercialization of VAL-083
to solve significant unmet medical needs.
VAL-083 is being studied in two collaborator-supported,
biomarker-driven Phase 2 clinical trials for MGMT-unmethylated GBM.
Overcoming MGMT-mediated resistance represents a significant unmet
medical need in the treatment of GBM. In addition, DelMar has
announced the allowance of a separate IND for VAL-083 as a
potential treatment for platinum-resistant ovarian cancer.
Further information on DelMar's clinical trials can be found on
clinicaltrials.gov:
https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs.
For additional information, please visit http://delmarpharma.com/;
or contact DelMar Pharmaceuticals Investor Relations:
ir@delmarpharma.com / (604) 629-5989.
Forward-Looking Statements
This communication contains
"forward-looking statements" based upon DelMar's and Adgero's
current expectations. within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
identified by terminology such as "may," "should," "expects,"
"plans," "anticipates," "could," "intends," "target," "projects,"
"contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negative of these terms or other similar words.
These statements are only predictions. DelMar and Adgero have based
these forward-looking statements largely on their then-current
expectations and projections about future events, as well as the
beliefs and assumptions of management. Forward-looking statements
are subject to a number of risks and uncertainties, many of which
involve factors or circumstances that are beyond each of DelMar's
and Adgero's control, and actual results could differ materially
from those stated or implied in forward-looking statements due to a
number of factors relating to the consummation of the Merger,
including but not limited to: (i) risks associated with
DelMar's and Adgero's ability to obtain the stockholder approval
required to consummate the proposed Merger and the timing of the
closing of the proposed Merger, including the risks that a
condition to closing would not be satisfied within the expected
timeframe or at all or that the closing of the proposed Merger will
not occur; (ii) the outcome of any legal proceedings that may
be instituted against the parties and others related to the Merger
Agreement; (iii) the occurrence of any event, change or other
circumstance or condition that could give rise to the termination
of the Merger Agreement, (iv) unanticipated difficulties or
expenditures relating to the proposed Merger, the response of
business partners and competitors to the announcement of the
proposed Merger, and/or potential difficulties in employee
retention as a result of the announcement and pendency of the
proposed Merger; (v) whether the combined business of Adgero
and DelMar will be successful, and (vi) those risks detailed
in DelMar's most recent Annual Report
on Form 10-K, the registration statement on Form S-4
related to the proposed Merger with Adgero and subsequent
reports filed with the SEC, as well as other documents that may be
filed by DelMar from time to time with the SEC. Accordingly, you
should not rely upon forward-looking statements as predictions of
future events. Neither DelMar nor Adgero can assure you that the
events and circumstances reflected in the forward-looking
statements will be achieved or occur, and actual results could
differ materially from those projected in the forward-looking
statements. The forward-looking statements made in this
communication relate only to events as of the date on which the
statements are made. Except as required by applicable law or
regulation, DelMar and Adgero undertake no obligation to update any
forward-looking statement to reflect events or circumstances after
the date on which the statement is made or to reflect the
occurrence of unanticipated events. Investors should not assume
that any lack of update to a previously issued "forward-looking
statement" constitutes a reaffirmation of that statement.
Additional Information and Where to Find It
This document is for informational purposes only and does not
constitute an offer to buy or sell or the solicitation of an offer
to buy or sell any securities or a solicitation of any vote or
approval. This presentation relates to the proposed Merger of
DelMar and Adgero. In connection with the proposed Merger,
DelMar has filed a registration statement on
Form S-4, which includes a document that serves as a
prospectus and proxy statement of DelMar (the "proxy
statement/prospectus"), and DelMar will file other documents
regarding the proposed Merger transaction with the U.S. Securities
and Exchange Commission (the "SEC"). No offering of securities
shall be made, except by means of a prospectus meeting the
requirements of Section 10 of the U.S. Securities Act of 1933,
as amended. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE
PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH
THE SEC CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME
AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT
STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING
THE PROPOSED MERGER. A definitive proxy statement/prospectus will
be sent to DelMar's stockholders. Investors and security
holders will be able to obtain these documents (when available)
free of charge from the SEC's website at www.sec.gov. The
documents filed by DelMar with the SEC may also be obtained
free of charge from DelMar by requesting them by mail at
DelMar Pharmaceuticals, Inc., 12707 High Bluff Drive, Suite 200,
San Diego, CA 92130.
Participants in the Solicitation
DelMar and its respective directors and executive officers
and other members of management and employees and certain of their
respective significant stockholders may be deemed to be
participants in the solicitation of proxies from DelMar
stockholders in respect of the proposed merger transaction.
Information about DelMar's directors and executive officers is
available in DelMar's proxy statement, filed June 2,
2020 for the 2020 Annual Meeting of Stockholders,
DelMar's Annual Report on Form 10-K for the fiscal
year ended June 30, 2019, which was filed with the SEC on
September 9, 2019 and DelMar's Current Report on
Form 8-K filed on September 9,
2019. Information regarding the persons who may, under the
rules of the SEC, be deemed participants in the proxy solicitation
and a description of their direct and indirect interests, by
security holding or otherwise, will be contained in the proxy
statement/prospectus and other relevant materials to be filed with
the SEC regarding the proposed merger transaction when they become
available. Investors should read the proxy statement/prospectus
carefully when it becomes available before making any voting or
investment decisions. You may obtain free copies of these documents
from the SEC and DelMar as indicated above.
No Offer or Solicitation
This presentation shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
No offering of securities shall be made except by means of a
prospectus meeting the requirements of Section 10 of the
Securities Act of 1933, as amended.
CONTACTS:
Investors:
CORE IR
516-222-2560
ir@coreir.com
Media:
Jules
Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-host-conference-call-to-discuss-proposed-acquisition-of-adgero-pharmaceuticals-301095288.html
SOURCE DelMar Pharmaceuticals, Inc.
